- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 3 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances | 303 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 3 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch | ||
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 131 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 119 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen | |
| 05.11.25 | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.10.25 | Lake Street Capital Markets initiates Genelux stock with Buy rating | 5 | Investing.com | ||
| 03.09.25 | GENELUX Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 08.08.25 | Genelux GAAP EPS of -$0.20 beats by $0.02 | 4 | Seeking Alpha | ||
| 07.08.25 | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 07.08.25 | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 171 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,810 | +3,12 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,310 | -3,68 % | RedHill Biopharma Ltd. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IMMUNIC | 0,578 | +0,52 % | EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones | Issuer: Immunic AG
/ Key word(s): Miscellaneous/Conference
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
07.01.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| CURIS | 0,785 | -0,63 % | Curis, Inc.: Curis Provides Third Quarter 2025 Business Update | Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,526 | +2,69 % | BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting | ||
| ESPERION | 2,660 | -5,51 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| CYBIN | 6,200 | +0,81 % | Neural Therapeutics, MindMed und Cybin: Psychedelika im Fokus eines Milliardenmarkts | ||
| KYNTRA BIO | 6,950 | -2,11 % | FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen | |
| KARYOPHARM | 5,500 | -1,79 % | Karyopharm Therapeutics Inc.: Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 | - Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 -
- Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer... ► Artikel lesen | |
| BIOLINERX | 2,345 | -0,64 % | BioLineRx Ltd. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PROTALIX BIOTHERAPEUTICS | 1,750 | +1,16 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| EDESA BIOTECH | 1,440 | -2,70 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal Year 2025 Results | TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 4,310 | 0,00 % | Can-Fite BioPharma Ltd.: Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction | RAMAT GAN, Israel, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 3,980 | +1,53 % | Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch | NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,200 | +1,96 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.